NATCO Pharma Ltd.
Research NATCO Pharma Ltd. (NATCOPHARM.NS) on Bullrun: market cap INR 144.45B, P/E 12.4, dividend yield 0.6%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNATCOPHARM.NS
- ExchangeNSE
- CountryIndia
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyINR
- Market capINR 144.45B
- P/E12.4
- Dividend yield0.6%
- Financial periodQ2 2026
- RevenueINR 7.35B
- Net incomeINR 2.07B
- Gross margin79.9%
Valuation Snapshot
latest market cap is INR 144.45B; P/E is 12.4; dividend yield is 0.6%.
Peer valuation comparison
Latest P/E is 12.39x versus a Healthcare sector median of 21.74x (43.0% below).
Latest dividend yield is 0.57% versus a Healthcare sector median of 2.4% (76.3% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | INR 144.45B | 12.4 | 0.8% | 5.95 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 5.95 INR, yield 0.6%.
About NATCO Pharma Ltd.
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Agrochemicals. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is NATCO Pharma Ltd.'s market cap?
NATCO Pharma Ltd.'s market capitalization is INR 144.45B.
What is NATCO Pharma Ltd.'s P/E ratio?
NATCO Pharma Ltd.'s price-to-earnings (P/E) ratio is 12.4.
Does NATCO Pharma Ltd. pay a dividend?
NATCO Pharma Ltd. has a dividend yield of 0.6%.
What does NATCO Pharma Ltd. do?
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Agrochemicals. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care.